BGF MDI HFO 320/14.4/9.6μg
D5985C00002
Phase 3 small_molecule completed
Quick answer
BGF MDI HFO 320/14.4/9.6μg for COPD (Chronic Obstructive Pulmonary Disease) is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- COPD (Chronic Obstructive Pulmonary Disease)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed